Jacobs Levy Equity Management’s Caribou Biosciences CRBU Stock Holding History

Jacobs Levy Equity Management’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$723K	Buy	410,979 +52,038	+14%	+$103K	﹤0.01%	771
2026 Q1	$682K	Sell	358,941 -465,358	-56%	-$799K	﹤0.01%	773
2025 Q4	$1.31M	Buy	824,299 +475,216	+136%	+$997K	0.01%	644
2025 Q3	$813K	Sell	349,083 -607,897	-64%	-$1.15M	﹤0.01%	755
2025 Q2	$1.21M	Sell	956,980 -485,141	-34%	-$477K	﹤0.01%	722
2025 Q1	$1.32M	Buy	1,442,121 +234,052	+19%	+$304K	0.01%	756
2024 Q4	$1.92M	Buy	+1,208,069	New	+$2.43M	0.01%	598
2023 Q3	–	Sell	-436,024	Closed	-$1.85M	–	982
2023 Q2	$1.85M	Buy	436,024 +403,804	+1,253%	+$1.81M	0.01%	588
2023 Q1	$171K	Buy	+32,220	New	+$201K	﹤0.01%	913

Other funds holding CRBU

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Jacobs Levy Equity Management's CRBU Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Caribou Biosciences (CRBU) stake by 14% in Q2 2026, buying an estimated $103K and bringing the position to 410,979 shares worth $723K. The position accounts for ﹤0.01% of the portfolio, ranked #771.

Jacobs Levy Equity Management first reported a position in CRBU in Q1 2023 and has held it in 9 quarters since. The position peaked at $1.92M in Q4 2024. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

Jacobs Levy Equity Management held 410,979 shares of Caribou Biosciences worth $723K as of Q2 2026.
Jacobs Levy Equity Management bought 52,038 Caribou Biosciences shares in Q2 2026, an estimated $103K.
Caribou Biosciences made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #771 holding.
Jacobs Levy Equity Management first reported a position in Caribou Biosciences in Q1 2023 and has held it in 9 quarters since.
Jacobs Levy Equity Management's Caribou Biosciences position peaked at $1.92M in Q4 2024.
137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.